+1-206-701-6702
+44-020-8133-4027
+81-50-5539-1737
+91-848-285-0837
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder, mainly occurred in children. ADHD is firstly diagnosed in childhood and often last till adulthood. The most common symptoms of ADHD are children may daydream a lot, forget or loose things, children may have hard time resisting temptation, have trouble taking turns, have difficulty getting along with others, children are overly active, and have trouble paying attention. Attention deficit hyperactivity disorder (ADHD) is treated with stimulant and non-stimulant drugs.
The global attention deficit hyperactivity disorder (ADHD) therapeutics market is estimated to be valued at US$ 18,169.0 million in 2020 and is expected to exhibit a CAGR of 7.1 % during the forecast period (2020-2027).
Figure 1. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Value (US$ Mn), 2016-2027
-therapeutics-market-fig-1.png "Attention Deficit Hyperactivity Disorder Treatment | CMI")
Increasing prevalence of attention deficit hyperactivity disorder is expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period. For instance, according to the study titled ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups’ published in the JAMA Network Open in November 2019, the prevalence of attention deficit hyperactivity disorder in adults among 7 racial and ethnic groups increased from 0.43% in 2007 to 0.96% in 2016.
Furthermore, key companies focusing on research and development in the treatment of attention deficit hyperactivity disorder are expected to propel growth of the global attention deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period. For instance, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc., a U.S. subsidiary, announced positive top-line results from phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of oral centanafadine, a novel investigational compound for the treatment of adult patients with attention deficit hyperactivity disorder.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 18,169.0 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 7.1% | 2027 Value Projection: | US$ 29,365.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Amneal Pharmaceuticals, Inc, Eli Lilly And Company, Janssen Pharmaceuticals, Inc, Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, and Purdue Pharma L.P. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Impact of Coronavirus (COVID-19)
Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 60.3 million infected individuals worldwide as of 26th November, 2020.
Furthermore, due to COVID-19 pandemic, the governments of various countries are taking initiatives to combat attention deficit hyperactivity disorder (ADHD) in children during the COVID-19 pandemic. For instance, according to the study published in the child and adolescent health, in THE LANCET journal, on April 17, 2020, it was found that during COVID-19 pandemic, the patients suffering from attention deficit hyperactivity disorder (ADHD) have become more vulnerable due to the stress caused by the pandemic.
Figure 2. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (%), By Region, 2020
-therapeutics-market-fig-2.png "Attention Deficit Hyperactivity Disorder Treatment | CMI")
North America is expected to hold dominant position in the global attention deficit hyperactivity disorder therapeutics market during the forecast period, owing to launch of products by players in the region. For instance, in March 2019, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received the U.S. Food and Drug Administration (FDA) approval for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII, for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged six years and older.
Key Players
Major players operating in the global attention deficit hyperactivity disorder (ADHD) therapeutics market include Amneal Pharmaceuticals, Inc, Eli Lilly And Company, Janssen Pharmaceuticals, Inc, Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, and Purdue Pharma L.P.
The global attention deficit hyperactivity disorder (ADHD) therapeutics market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, and Combined Presentation and various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight.
Market Dynamics
Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company in the U.S., received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is a captivating video game experience to improve attention in children suffering from ADHD.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
